Showing Results for: “Glycemic Index and Diabetes”

People with diabetes are three times as likely to need hospitalization if infected with COVID-19 With the diabetes community at greater risk for complications during the COVID-19 pandemic, the American Diabetes Association® (ADA) and Sun Life partnered to reinvent this year’s annual Call to Congress to educate advocates on COVID-19 and diabetes, and how to support people with diabetes during the pandemic. Usually an in-person gathering of ADA Advocates on Capitol Hill, the recent virtual town hall event informed and engaged the diabetes advocate community about legislative goals specific to

Los nuevos lineamientos incluyen actualizaciones a las recomendaciones sobre obesidad, hipertensión, medicamentos para insuficiencia cardiaca, determinantes sociales de la salud, y gestión de los niveles de lípidos. El día de hoy, la Asociación Americana de la Diabetes (ADA, por sus siglas en inglés), publicó los Estándares de Cuidados para Diabetes— 2023 (Estándares de Cuidados) , lineamientos integrales, basados en evidencia, para la prevención, el diagnóstico y tratamiento de la diabetes. Con base en la investigación científica y los estudios clínicos más recientes, los Estándares de

The ADA asks you to raise your voice, mark your fist and share your image on social media using #CountMeInADA This November, the American Diabetes Association (ADA) is highlighting the numbers that matter most when it comes to those living with, at risk and supporting those with diabetes. Count Me In is not just an awareness campaign; it is a call to action for all of us. Visit diabetes.org/CountMeInADA to answer the call today. On November 1st, to kick off American Diabetes Month, show your solidarity, whether you have diabetes, you’re supporting someone who has it, or you’re a caregiver

Social Determinants of Health grant will provide community gardens and diabetes support to people in low-income areas in Alabama The American Diabetes Association® (ADA) and The Pfizer Foundation have joined forces to address food insecurity and high rates of diabetes in communities in Montgomery, Alabama. The Foundation grant is part of ADA’s Health Equity Now national platform to ensure that all people living with diabetes, and the millions of underserved Americans who are at greatest risk for diabetes, have equal access to resources that they require not just to survive, but to thrive. The

On October 5, 2021, Medtronic announced the expansion of two recalls on MiniMed 600 series insulin pumps for incorrect insulin dosing and remote controllers used with Paradigm and 508 MiniMed insulin pumps for potential cybersecurity risks. The U.S. Food and Drug Administration (FDA) has identified both of these as Class I recalls, the most serious type of recall. People with diabetes who are currently using a MiniMed 600 series insulin pump and are unsure if their device is affected, should refer to the Medical Device Recalls database or use the Medtronic Pump Serial Number Look-up Tool . If

People with type 2 diabetes should be considered in remission after sustaining normal blood glucose (sugar) levels for three months or more, according to a new consensus statement from the American Diabetes Association ® (ADA), the Endocrine Society, the European Association for the Study of Diabetes and Diabetes UK jointly published in Diabetes Care , the J ournal of Clinical Endocrinology & Metabolism , Diabetologia , and Diabetic Medicine , respectively. About 10% of the U.S. population has diabetes , and these numbers continue to rise. People with type 2 diabetes can achieve “remission” by

Study shows diabetes patients not taking medication experienced longer hospitalization and recovery with greatest toll among Latinx populations A new study reveals unmanaged diabetes is a key factor in COVID-19 severity and complications, particularly among Hispanic and Latinx populations. Findings of the retrospective study were presented at the virtual 81st Scientific Sessions of the American Diabetes Association ® (ADA). Forty percent of Americans who have died of COVID-19 have had diabetes, and 1 in 10 people with diabetes hospitalized for COVID-19 die within one week – making diabetes a

“This is an historic moment for all people affected by type 1 diabetes (T1D). The approval of Teplizumab, the first-ever treatment approved for the delay of T1D, is a significant step forward for everyone impacted by this chronic disease. People with T1D require life-long insulin replacement therapy, so to be able to provide an individual with a 2-year delay from the symptoms and burden of T1D is a tremendous accomplishment as we look towards finding a cure. There will likely be long-term benefits for blood glucose management and the reduction or delay of acute and long-term complications. The